基于 TCGA 数据库的回顾性研究：SOX6 和 SOX12 作为透明细胞肾细胞癌预后生物标志物的鉴定。

Identification of SOX6 and SOX12 as Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma: A Retrospective Study Based on TCGA Database.

机构信息

Department of Urology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.

Department of Urological Surgery, Shanxi Medical University, Taiyuan, Shanxi, China.

出版信息

Dis Markers. 2021 Nov 26;2021:7190301. doi: 10.1155/2021/7190301. eCollection 2021.

DOI:10.1155/2021/7190301

PMID:34868396

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8642026/

Abstract

BACKGROUND

The SOX gene family has been proven to display regulatory effects on numerous diseases, particularly in the malignant progression of neoplasms. However, the molecular functions and action mechanisms of SOX genes have not been clearly elucidated in clear cell renal cell carcinoma (ccRCC). We aimed to explore the expression status, prognostic values, clinical significances, and regulatory actions of SOX genes in ccRCC.

METHODS

RNA-sequence data and clinical information derived from The Cancer Genome Atlas (TCGA) database was used for this study. Dysregulated SOX genes between the normal group and ccRCC group were screened using the Wilcoxon signed-rank test. The Kaplan-Meier analysis and univariate Cox analysis methods were used to estimate the overall survival (OS) and disease-specific survival (DSS) differences between different groups. The independent prognostic factors were identified by the use of uni- and multivariate assays. Subsequently, the Wilcoxon signed-rank test or Kruskal-Wallis test and the chi-square test or Fisher exact probability methods were employed to explore the association between clinicopathological variables and SOX genes. Finally, CIBERSORT was applied to study the samples and examine the infiltration of immune cells between different groups.

RESULTS

Herein, 12 dysregulated SOX genes in ccRCC were screened. Among them, two independent prognostic SOX genes (SOX6 and SOX12) were identified. Further investigation results showed that SOX6 and SOX12 were distinctly associated with clinicopathological features. Furthermore, functional enrichment analysis revealed that SOX6 and SOX12 were enriched in essential biological processes and signaling pathways. Finally, we found that the SOX6 and SOX12 expression levels were correlated with tumor-infiltrating immune cells (TIICs).

CONCLUSION

The pooled analyses showed that SOX6 and SOX12 could serve as promising biomarkers and therapeutic targets of patients with ccRCC.

摘要

背景

SOX 基因家族已被证明对许多疾病具有调节作用，特别是在肿瘤的恶性进展中。然而，SOX 基因在透明细胞肾细胞癌（ccRCC）中的分子功能和作用机制尚不清楚。我们旨在探讨 SOX 基因在 ccRCC 中的表达状态、预后价值、临床意义和调控作用。

方法

本研究使用来自癌症基因组图谱（TCGA）数据库的 RNA-seq 数据和临床信息。使用 Wilcoxon 符号秩检验筛选正常组和 ccRCC 组之间失调的 SOX 基因。使用 Kaplan-Meier 分析和单变量 Cox 分析方法估计不同组之间的总生存期（OS）和疾病特异性生存期（DSS）差异。使用单变量和多变量分析确定独立的预后因素。然后，使用 Wilcoxon 符号秩检验或 Kruskal-Wallis 检验和卡方检验或 Fisher 确切概率法探索临床病理变量与 SOX 基因之间的关系。最后，使用 CIBERSORT 研究样本并检查不同组之间免疫细胞的浸润。

结果

在此，筛选出 ccRCC 中 12 个失调的 SOX 基因。其中，鉴定出两个独立的预后 SOX 基因（SOX6 和 SOX12）。进一步的研究结果表明，SOX6 和 SOX12与临床病理特征明显相关。此外，功能富集分析表明，SOX6 和 SOX12富集在重要的生物学过程和信号通路中。最后，我们发现 SOX6 和 SOX12 的表达水平与肿瘤浸润免疫细胞（TIIC）相关。